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ABSTRACT: Nitric oxide synthase (NOS) plays a major role in a number of key physiological and pathological processes and it is important to understand how this enzyme is regulated. The small acidic calcium binding protein, calmodulin (CaM), is required to fully activate the enzyme.
The exact mechanism of how CaM activates NOS is not fully understood at this time. Studies have shown CaM to act like a switch that causes a conformational change in NOS to allow for the electron transfer between the reductase and oxygenase domains through a process that is thought to be highly dynamic and at least in part controlled by several possible phosphorylation sites. We have determined the solution structure of CaM bound to a peptide that contains a phosphorylated threonine corresponding to Thr495 in full size eNOS in order to investigate the structural and functional effects that the phosphorylation of this residue may have on nitric oxide production. Our biophysical studies show that phosphorylation of Thr495 introduces electrostatic repulsions between the target sequence and CaM as well as a diminished propensity for the peptide to form an -helix. The calcium affinity of the CaM-target peptide complex is reduced due to phosphorylation and this leads to weaker binding under low physiological calcium concentrations. This study provides an explanation for the reduced NO production by eNOS carrying a phosphorylated Thr495 residue.
Nitric oxide synthase (NOS) enzymes (E.C. 1.14.13.39) catalyze the production of nitric oxide (•NO) that acts as a secondary inter-and intracellular messenger involved in many physiological processes. 1 Three NOS isozymes are found in mammals: neuronal NOS (nNOS, NOS I), endothelial NOS (eNOS, NOS III), and inducible (iNOS, NOS II). The NOS enzymes are homodimeric with each monomer containing an N-terminal oxygenase domain, which contains binding sites for the catalytic heme, tetrahydrobiopterin (H4B), and the substrates L-arginine and molecular oxygen, and a C-terminal reductase domain, which contains binding sites for the cofactors FMN, FAD, and NADPH. A Calmodulin (CaM) binding domain connects the oxygenase and reductase domains and is required for efficient electron transfer from the reductase to the oxygenase domain for •NO production. hydrophobic patches that allow it to associate with its intracellular target proteins. The flexibility of CaM's central linker separating the N-and C-domains allows it to adapt its conformation to optimally associate with its intracellular targets. 5, 6 Both the N-and C-lobes must be calcium replete to fully activate eNOS and nNOS enzymes. 7, 8 eNOS activity is regulated by multiple mechanisms, including posttranslational modifications such as protein phosphorylation. 9, 10 The binding of CaM and the transfer of electrons from the reductase to the oxygenase domain of eNOS is dependent on protein phosphorylation and dephosphorylation. 9 eNOS can be phosphorylated on serine, tyrosine and threonine residues and contains many potential phosphorylation sites that can play a role in regulating its activity.
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Phosphorylation of Ser1177 in the reductase domain has been found to result in the activation of eNOS, whereas the phosphorylation of Thr495 within the CaM-binding domain has been found to reduce eNOS activity. [15] [16] [17] Perturbations of eNOS phosphorylation have been reported in a number of diseases. 18 Phosphorylation of Thr495 acts as a negative regulatory site and has been reported to interfere with the binding of CaM to the CaM-binding domain affecting activation of the enzyme. 9, 15 There is considerable interest in understanding the structural and functional effects that the phosphorylation of Thr495 in eNOS has on the calcium dependent CaM binding and activation of the enzyme. In the present study the structural and functional effects that the phosphorylation of eNOS has on binding to CaM were investigated. [23] [24] [25] In addition, dihedral angle restraints were derived from chemical shift analysis with TALOS+. 26 CNSsolve version 1.2 27 was used to perform the structure calculations using standard simulated annealing protocols.
Delphi Calculation of the CaM Structures.
Delphi electrostatic potentials of the structure was calculated using the DelPhiController interface of UCSF Chimera 1.5.3 (build 33475). 28 The parseRes atomic radii file and atomic charge file were used as the input files in the calculation.
The electrostatic potential surface was visualized in Chimera.
Dansylation of CaM. Dansyl-CaM was prepared as previously described. 29 CaM (1 mg/ml) was buffer exchanged into 10 mM NaHCO3, 1 mM EDTA, pH 10.0, at 4°C. 30 μl of 6 mM dansyl-chloride (1.5 mol/mol of CaM) in DMSO was added to 2 ml of CaM, with stirring. After incubation for 12 hr at 4°C, the mixture was first exhaustively dialyzed against 500 volumes of 150 mM NaCl, 1 mM EDTA, 20 mM Tris-HCl, pH 7.5, at 4°C, then exhaustively dialyzed against 500 volumes of water. Labeling yields were determined from absorbance spectra using the ε320 of 3,400 M -1 cm -1 and were compared to actual protein concentrations determined using the Bradford method with wild-type CaM used as the protein standard. 30 Isothermal Titration Calorimetry. All ITC recordings were performed on a Microcal ITC200 from Microcal (Northampton, MA) at 25°C, 1000 rpm stir speed, and reference power set to 5 µcal/s. In the experiments at saturating Ca 2+ concentrations the buffer used was 30 mM MOPS, 100 mM KCl, pH 7.2 and 1 mM CaCl2 and was identical between cell and syringe. In the experiments at 225 nM free Ca 2+ the calcium calibration buffer kit from Invitrogen was used and the buffer consisted of 15 mM MOPS, 50 mM KCl, pH 7.2 10 mM EGTA and 6.0 mM CaEGTA and was identical between cell and syringe. Buffer into buffer, peptide into buffer and buffer into CaM controls showed no significant baseline decay or drift and relatively low, consistent heats of injection, indicating sufficiently matched cell and syringe buffer conditions.. 39 µL of each peptide was titrated into 200 µL of CaM at varying concentrations (optimal starting conditions were determined empirically), typically from 100 µM peptide into 10 µM
CaM to 500 µM peptide into 50 µM CaM, over the course of 20-30 injections at 2-3 min intervals. Data analysis was performed using Origin ITC200 Origin70 module with pre-loaded fitting equations for one-and two-sites models. The one-set-of-sites model was found to be applicable to all experiments.
Circular Dichroism (Spectropolarimetry). CD was performed using a Jasco J-715 CD spectropolarimeter and analyzed using J-715 software(Jasco Inc., Easton, MD, USA) as 
RESULTS AND DISCUSSION
CD and NMR Spectroscopy. NMR spectroscopy was used to assess changes to the CaMeNOS complex due to the phosphorylation of Thr495. Figure 1a shows the overlay of the 15 N-HSQC spectra of CaM-eNOS with that of CaM-eNOSpThr495. Cross peaks for the majority of amides in the CaM-eNOSpThr495 complex overlap with those of CaM-eNOS complex.
However, amides in the C-domain, specifically the amides of residues in EF hand IV, do not overlap with those of CaM-eNOS due to differences in chemical shifts. Also not seen in Figure   1a is the chemical shift difference of E7, which is located in the heavily overlapped central portion of the spectra. This data suggests that the structures of the CaM-eNOS complex and the CaM-eNOSpThr495 complex are quite similar. This provides further evidence that this phosphorylation affects residues E7 and E127, which are in close proximity to the phosphorylated Thr495 in the structure. This has been previously postulated by Aoyagi et al.
when they suggested that the addition of a negatively charged phosphate group would cause electrostatic repulsion between E7 and E127. 31 The effect of phosphorylation on the secondary structure of the peptide was investigated using trifluoroethanol (TFE) monitored by circular dichroism spectroscopy. The TFE is used to mimic hydrophobic environments and is known to induce α-helical conformation in peptides that have a propensity to form this secondary structure. Both eNOS peptides showed no apparent structure in the buffer solution with 0% TFE. A comparison of the tendency of each peptide to form an α-helix was then performed by recording spectra after the addition of increasing concentrations of TFE. The formation of an α-helix is generally accompanied by the appearance of negative ellipticity at 208 and 222 nm. Both peptides showed increased amounts of secondary structure as more TFE was added. In both cases, there was an increase in apparent α-helical structure with increasing TFE concentration. With increasing concentrations of TFE, the negative ellipticity at 222 nm of both peptides plateau at TFE concentrations above 30% (see Figure 1b) . While this result indicates that the increase in helical structure does not appreciably change above 30% TFE, the phosphorylated peptide did not show as large an α-helical content as the nonphosphorylated peptide (Figure 1b) . The structural effects of the phosphorylation leading to the diminished helical structure of the peptide can be due to the charged and bulky nature of the phosphate, destabilization of electrostatics that can result in nonproductive interaction with neighboring residues or the high desolvation penalty of the side chain. 32 Specifically, it has been previously proposed that phosphorylation at Thr495 OG1 would disrupt its hydrogen bond with the Glu498 backbone amide, possibly affecting the α-helical secondary structure of the peptide.
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In addition, the Thr495 is next to one of the anchoring residues in the classical '1-5-8-14' CaM binding sequence motif. A negatively charged phosphorylated Thr495 next to the first residue of the motif will likely disrupt the helical structure of the region.
While the propensity of the phosphorylated eNOS CaM binding domain to form an -helix appears to be diminished, the final structure of the peptide bound to CaM is very similar to that of the nonphosphorylated form of the peptide. The diminished -helical propensity could account for the reduced activity of the enzymes associated with the phosphorylated form.
Structure of CaM-eNOSpThr495 CaM Binding Peptide Complex. The three dimensional solution structure of CaM bound to the human eNOS CaM binding domain peptide phosphorylated at Thr495 (CaM-eNOSpThr495) was determined using multi-dimensional heteronuclear NMR spectroscopy. The structure of the complex is based on a large number of experimental constraints and is well defined. Structure and input data statistics are summarized in Table 1 . The family of 20 final structures is shown in Figure 2a . The average structure showing the location of the phosphorylation of Thr495 of the eNOS peptide, which is found near the N-terminal end of the peptide is shown in Figure 2b . Residues 1-4 (corresponding to 491-494 of eNOS) at the N-terminus of the eNOSpThr495 CaM binding region peptide were not included in the structure calculation because they could not be unambiguously assigned. This could be due to the addition of the phosphate group which has been theorized to destabilize the helical propensity of the peptide. 31 Based on the comparison of the 15 N-double filtered NOESY experiments for CaM with eNOS peptide and CaM with eNOSpThr495 peptide there was little change in the chemical shifts observed for pThr495 and Thr495.
Comparison of the CaM-eNOS vs CaM-eNOSpThr495 Complexes.
When the solution structure of CaM-eNOS is superimposed onto that of the CaM-eNOSpThr495 structure, the two structures are shown to be quite similar, however, a few local differences are seen ( Figure 3 ).
When aligned with respect to the backbone atoms of the peptide, a difference is shown in the orientation of helix A of CaM between the two structures, with helix A of CaM-eNOSpThr495 pushed away from the N-terminus of the peptide (where the phosphorylated Thr495 is located).
EF hand IV (colored blue) is also shifted farther away from the peptide in the CaMeNOSpThr495 structure. The rest of the CaM-eNOSpThr495 structure superimposes quite well on the CaM-eNOS structure. This, along with the 15 N-HSQC spectra overlay, confirms that the phosphorylation of Thr495 doesn't have an effect on the structure of CaM away from the site of the phosphorylation.
Electrostatic Effects of the Phosphorylation of Thr495. The addition of the phosphate group
to Thr495 of the eNOS peptide shows structural effects on EF hands I and IV. This is first illustrated by the 15 N-HSQC spectra overlay of the CaM-eNOS and CaM-eNOSpThr495 complexes ( Figure 1a ) and is clearly shown by the structure overlay of the two structures ( Figure   3 ). The analysis of the CaM-eNOSpThr495 structure with DelPhi illustrates that this modification to the peptide creates a more negative potential on the N-terminal region of the peptide, which is located in a negatively charged region of CaM (Figure 4b, d ). This negative charge is not present in the CaM-eNOS complex (figure 4c) and thus would not cause any electrostatic repulsion. This phosphate group is in close proximity to E7, which is found in helix A of EF hand I, and E127, found in helix G of EF hand IV. The electrostatic repulsion between the phosphate group and helix A of EF hand I gives an explanation as to why helix A is pushed further from the peptide in the CaM-eNOSpThr495 complex, as shown in Figure 3 . This also explains why helix G and EF hand IV are shifted further away from the eNOSpThr495 peptide.
This electrostatic repulsion could be affecting CaM's ability to coordinate Ca 2+ by interfering with the EF hands I and IV, which would help explain why CaM has diminished ability to bind eNOS phosphorylated at Thr495 at physiological Ca 2+ levels. 35, 36 all of our experiments were performed by ITC using exactly the same conditions. Representative titrations for each are shown in figure 6 . In the presence of excess calcium (1mM) wild type eNOS peptide binds to CaM by an exothermic interaction. As previously reported for the binding of the nNOS peptide, 37 eNOS binding proceeds with a negative enthalpy (ΔH) and a positive entropy (ΔS) and modest affinity (Kd = 0.7µM). This indicates that the interaction is driven by favorable enthalpy and entropy. In contrast, the binding of the eNOSpThr495 peptide under the same conditions is weakly endothermic, with a comparable affinity to that of wild type (Kd = 0.3µM). A similar endothermic interaction has been reported for apoCaM titrated with mutant peptides corresponding to the CaM binding domain of iNOS, an isoform that is known to bind to CaM in the absence of calcium. 38 The eNOSpThr495 binding interaction proceeds with positive ΔH and ΔS. The interaction is therefore driven by the increase in entropy. Both peptides showed a 1:1 stoichiometry with CaM as expected.
Fluorescence Spectroscopy Suggests Increased
Since our fluorescence studies showed an apparent difference in binding at low calcium concentrations, we attempted to thermodynamically characterize the interactions under these conditions. Intriguingly, at low [Ca 2+ ] free , the binding of wild type eNOS peptide to CaM becomes highly endothermic, the entropy gain increases over fourfold, and its affinity for CaM increases slightly (K d = 0.2µM). A similar result showing a switch from an exothermic to an endothermic interaction has been reported for the binding of the nNOS CaM target domain to
CaM by simply changing the experimental conditions going from a higher to a lower temperature. 37 The ΔH under low 225nM calcium conditions is now positive and unfavorable for binding. The change in enthalpy is compensated by a much larger positive ΔS than that observed for the wild type peptide binding in excess calcium. In contrast, the binding of eNOSpThr495 to CaM in these low [Ca 2+ ]free conditions becomes negligible ( Figure 6 ). This is consistent with our fluorescent experiments showing no apparent binding under these conditions. In essence, these results indicate that non-phosphorylated eNOS is more sensitive to ambient cellular Ca 2+ , and phosphorylation serves as an attenuator of Ca 2+ -CaM regulation of eNOS.
We set out to understand how phosphorylation of a single residue in the CaM target domain results in diminished NOS enzyme activity. Previous studies had shown that an eNOS enzyme carrying a phosphomimetic mutation T495D binds very weakly to CaM. In contrast, the control mutant T495A showed strong binding to CaM. 15 Enzyme studies also showed that only phosphorylation of T495 or the mutation T495D resulted in the loss of eNOS enzyme activity. It had been postulated that phosphorylation of T495 reduces output by hindering the association of CaM with its binding site. 31 Until the present study, there had not been a structural study using a phosphorylated T495 residue. Our solution structure shows that in the presence of excess calcium, phosphorylation does not prevent the binding of CaM to the phosphorylated peptide.
While the exact mechanism of how phosphorylation of Thr495 in eNOS adversely affects the activation of the enzyme is still unknown, a careful look at the complex does provide some idea of the reported cause for the reduced enzyme activity. A comparison of the two structures in figures 1 and 2 show that the most significant changes in the pThr495 solution structure involved two CaM amino acids E7 and E127. In addition both E11 and M124 are found to be in close proximity to the pThr495 phosphate group. The previously reported crystal structure of CaM bound to the human eNOS peptide shows that the side chains of these amino acids are in contact with a number of amino acids in the eNOS peptide. 31 Both E7 and E11 are part of helix A of the EF hand 1 in CaM. The E7 side chain is in contact with eNOS residues K497 and E498 and has ionic interactions with R492. The E11 side chain is in contact with eNOS residues E498, A502
and I505 and has a hydrogen bond with N501. Our results shown in Figure 3 indicate that helix A is pushed away from the peptide likely due to electrostatic repulsion.
The M124 and E127 residues are both in helix G of EF hand 4 in CaM. The side chain of M124 is in contact with eNOS residues T495, F496 and V499. Residue E127 of CaM has contact with T495 and K497. In addition E127 has ionic interactions with K493 and the backbone of T496. Electrostatic repulsion could again account for the displacement of helix G of EF hand 4
away from the peptide (Figure 3) . Looking closely at the Delphi image with the phosphate present, the phosphorylation of Thr495 adds a negative charge that is close to helix G (Figure 4 ).
The displacement of helix A and G may not be significant under conditions with 1 mM calcium, but under physiological low calcium concentration conditions, a more significant displacement of these helices may have a detrimental effect on enzyme binding and activation. This comes from our dansyl-CaM experiments showing that the pThr495 peptide required significantly higher concentrations of calcium to bind to CaM. Our calorimetric study also showed a lack of binding of CaM to the phosphorylated peptide in the presence of 225nM free calcium. We used TFE to induce α-helical formation and used spectropolarimetry to monitor the changes in the secondary structure of the two eNOS peptides. The secondary structure of both peptides plateaus in 30% TFE but phosphorylation appears to result in a reduction in the degree of α-helical structure in the peptide. In the presence of high concentrations of calcium, the solution structure
shows that both peptides form an α-helical structure when bound to CaM.
In summary, the interactions of CaM with the peptides based on the eNOS CaM binding domain or the eNOS CAM binding domain phosphorylated at Thr495 are very similar at saturating Ca 2+ concentrations. This is confirmed by our NMR spectroscopy (see Figure S2, 
